Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Tonix is a fully integrated biotechnology company, publicly traded on NASDAQ (ticker: TNXP), with marketed products and a pipeline of development candidates. The Company is focused on commercializing, developing, discovering, and licensing therapeutics to treat and prevent human disease. In August 2025, Tonix received FDA approval for Tonmya™ (cyclobenzaprine HCl sublingual tablets), a first-in-class, once-daily, non-opioid treatment for fibromyalgia. Tonmya is the first new fibromyalgia therapy approved in over 15 years, following successful Phase 3 trials demonstrating significant symptom improvement. Commercial launch is expected in the fourth quarter of 2025.
Tonix also markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg, both indicated for the treatment of acute migraine with or without aura in adults. Tonix’s development portfolio includes product candidates in central nervous system (CNS), immunology, immuno-oncology infectious disease and rare disease. The CNS pipeline features both small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions. The immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer. The infectious disease pipeline includes a vaccine in development to prevent smallpox and monkeypox, which also serves as a live virus vaccine platform for other infectious diseases. Finally, the rare disease portfolio includes a product in development for Prader-Willi syndrome, which has both orphan drug designation and rare pediatric disease designation grants from the FDA.
Tonix owns and operates a state-of-the art infectious disease research facility in Frederick, Md.
Please visit www.Tonixpharma.com for specifics on the pipeline.
All of Tonix’s product candidates are investigational new drugs or biologics and have not been approved for any indication.
The Associate Director Thought Leader Liaison (TLL), Fibromyalgia, will directly report into the Director, Commercial Strategy and will lead executional efforts in regional and local engagement with existing and emerging Key Opinion Leaders (KOLs), Advocacy Groups and Professional Societies to develop and implement education that helps simplify the early Fibromyalgia patient journey from diagnosis through treatment and monitoring. This will include identifying new and emerging opinion leaders and appropriately engaging KOLs to support speaker bureau activities, and assessing speaker programs for meaningfulness, effectiveness, education, and compliance with company policies. The TLL role is a field-based role (non-sales focused) position, working closely with U.S. Key Fibromyalgia Thought Leaders (KOLs) to ensure cross-functional commercial resources are made available as appropriate. The three primary (but not exclusive) areas of focus for TLL are KOL engagement, executive encounter management, and supporting the Fibromyalgia community.
$130,000 - $200,000 USD
*Please note that Tonix does not offer sponsorship for this role.
Tonix does not accept agency resumes unless contacted directly by internal Tonix Talent Acquisition. Please do not forward resumes to Tonix employees or any other company location; Tonix is not responsible for any fees related to unsolicited resumes.
Tonix provides a comprehensive compensation and benefits package which includes:
Tonix provides equal employment opportunities (EEO) to all employees and applicants for employment without regard to race, color, religion, sex, national origin, age, genetics, or any other characteristic protected by law. In addition to federal law requirements, Tonix complies with applicable state and local laws governing nondiscrimination in employment. This policy applies to all terms and conditions of employment, including recruiting, hiring, placement, promotion, termination, layoff, recall, transfers, leaves of absence, compensation, and training. Tonix expressly prohibits any form of workplace harassment based on race, color, religion, gender, sexual orientation, gender identity or expression, national origin, age, genetic, information, disability, veteran status, or any other characteristic protected by law.